commercialization
Under the deal, MedRhythms would receive a $3 million upfront payment and could earn up to $117.5 million if certain milestones are met.
The companies will be collaborating on a prescription digital therapeutic for patients with schizophrenia built on Click Therapeutics' tech platform.